Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cherry lamotrigine ODT · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo. |
| Group 2 | EXPERIMENTAL | To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo. |
| Name | Type | Description |
|---|---|---|
| Cherry lamotrigine ODT | DRUG | 25mg, taken orally on one study visit |
| Cherry Placebo | DRUG | Taken orally on one study visit |
Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria apply: * Healthy as judged by the responsible physician or designee. No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical ...
Cherry lamotrigine ODT is an investigational small molecule being developed by GSK plc for the treatment of Mental Disorders. It is an orally disintegrating tablet formulation of lamotrigine, a drug used in psychiatry. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Cherry lamotrigine ODT is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical trials and is not yet approved for commercial use.
Cherry lamotrigine ODT is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and properties. One Phase 1 trial has been completed.
Cherry lamotrigine ODT has one completed Phase 1 clinical trial, identified as NCT01607086. This study compared the properties and characteristics of an investigational formulation of lamotrigine with placebo in 24 participants with Mental Disorders. The trial was conducted in the United Kingdom and enrolled healthy volunteers aged 18 years and older.
Cherry lamotrigine ODT is a specific oral disintegrating tablet formulation of lamotrigine, developed by GSK plc. It is being studied for use in Mental Disorders. The drug is in Phase 1 clinical development and is not yet approved.